Innoviva, Inc. (INVA)
NASDAQ: INVA · Real-Time Price · USD
21.20
+0.36 (1.73%)
At close: Sep 16, 2026, 4:00 PM EDT
21.20
0.00 (0.00%)
After-hours: Sep 16, 2026, 4:04 PM EDT
Innoviva Market Cap
Innoviva has a market cap or net worth of $1.53 billion as of September 16, 2026. Its market cap has increased by 24.31% in one year.
Market Cap
1.53B
Enterprise Value
1.28B
1-Year Change
24.31%
Ranking
Category
Stock Price
$21.20
ChartMarket Cap Chart
Since October 5, 2004, Innoviva's market cap has increased from $743.40M to $1.53B, an increase of 106.03%. That is a compound annual growth rate of 3.35%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 16, 2026 | 1.53B | 2.48% |
| Dec 31, 2025 | 1.49B | 37.61% |
| Dec 31, 2024 | 1.09B | 5.65% |
| Dec 29, 2023 | 1.03B | 11.18% |
| Dec 30, 2022 | 924.60M | -22.87% |
| Dec 31, 2021 | 1.20B | -4.58% |
| Dec 31, 2020 | 1.26B | -12.40% |
| Dec 31, 2019 | 1.43B | -18.66% |
| Dec 31, 2018 | 1.76B | 15.03% |
| Dec 29, 2017 | 1.53B | 31.74% |
| Dec 30, 2016 | 1.16B | -6.00% |
| Dec 31, 2015 | 1.24B | -24.18% |
| Dec 31, 2014 | 1.63B | -48.60% |
| Dec 31, 2013 | 3.18B | 81.10% |
| Dec 31, 2012 | 1.75B | 15.68% |
| Dec 30, 2011 | 1.52B | 16.20% |
| Dec 31, 2010 | 1.30B | 94.91% |
| Dec 31, 2009 | 669.40M | 8.40% |
| Dec 31, 2008 | 617.50M | -35.48% |
| Dec 31, 2007 | 957.00M | -35.96% |
| Dec 29, 2006 | 1.49B | 30.34% |
| Dec 30, 2005 | 1.15B | 49.85% |
| Dec 31, 2004 | 765.10M | 2.92% |
| Oct 5, 2004 | 743.40M | - |
View and export this data all the way back to 2004. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Intellia Therapeutics | 1.63B |
| Immunocore Holdings | 1.62B |
| AnaptysBio | 1.59B |
| Syndax Pharmaceuticals | 1.58B |
| Latigo Biotherapeutics | 1.55B |
| Novavax | 1.54B |
| Avalyn Pharma | 1.54B |
| Inhibrx Biosciences | 1.53B |